Abstracts tagged "Lupus nephritis"

Abstract Number: 1484 • ACR Convergence 2021
B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis
Fatima Alduraibi¹, Huma Fatima¹, Winn Chatham², Hui-Chen Hsu¹ and John Mountz¹, ¹University of Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Our laboratory previously demonstrated a strong association of B cell intracellular interferon beta (IFNβ) with the development of anti-Smith/ribonuclear protein (Sm/RNP), anti-DNA, and lupus…
Abstract Number: 1936 • ACR Convergence 2021
A Neutrophil Degranulation Signature Identifies Proliferative Lupus Nephritis
Andrea Fava¹, Jessica Li¹, Daniel Goldman², Brendan Antiochos¹, Jose Monroy-Trujillo¹, Derek Fine¹, Mohamed G. Atta¹, Jill Buyon³, Joel Guthridge⁴, Judith James⁴, Michelle Petri² and Accelerating Medicines Partership (AMP) RA/SLE Network⁵, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NYU School of Medicine, New York, NY, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Brigham and Women's Hospital, Everett, MA
Background/Purpose: The identification of intrarenal pathological processes is key to develop better diagnostic and treatment strategies in lupus nephritis (LN). But the direct comprehensive study…
Abstract Number: 0341 • ACR Convergence 2021
Addition of Narrative Text Abstraction to ICD-Based Abstraction Significantly Improves Identification of Lupus Nephritis in Real-World Data
Meghan Tierney and Chris Rowe, PicnicHealth, San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is often underrecognized and difficult to identify retrospectively, presenting challenges for clinicians and researchers hoping to explore this condition using real-world…
Abstract Number: 0966 • ACR Convergence 2021
Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis
Garett Dunlap¹, Allison Billi², Feiyang Ma³, Johann Gudjonsson², J. Michelle Kahlenberg⁴ and Deepak Rao⁵, ¹Harvard University, Somerville, MA, ²Department of Dermatology, University of Michigan, Ann Arbor, MI, ³University of California Los Angeles, Los Angelas, CA, ⁴University of Michigan, Ann Arbor, MI, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is commonly present in patients with systemic lupus erythematosus (SLE), but can also exist as an isolated manifestation without further…
Abstract Number: 1485 • ACR Convergence 2021
Glycosphingolipids: Potential Urine Biomarkers of Therapeutic Response in Lupus Nephritis
Tammy Nowling, Jessalyn Rodgers, Bethany Wolf, Brian Troyer and Jim Oates, Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a chronic, immune complex-mediated glomerulonephritis affecting up to 60% of patients with lupus. Progression of the most aggressive forms of…
Abstract Number: 1937 • ACR Convergence 2021
IL-16 Is Linked to Lupus Nephritis Activity
Andrea Fava¹, Deepak Rao², Chandra Mohan³, Ting Zhang³, Avi Rosenberg¹, Paride Fenaroli⁴, H. Michael Belmont⁵, Peter Izmirly⁶, Robert Clancy⁷, Jose Monroy-Trujillo¹, Derek Fine¹, Arnon Arazi⁸, Celine Berthier⁹, Anne Davidson¹⁰, Judith James¹¹, Betty Diamond¹², Nir Hacohen¹³, David Wofsy¹⁴, Soumya Raychaudhuri², Accelerating Medicines Partership (AMP) RA/SLE Network¹⁵, Jill Buyon⁵, Michelle Petri¹⁶ and The Accelerating Medicines Partnership in RA/SLE¹⁷, ¹Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³University of Houston, Houston, TX, ⁴Universita` degli Studi di Parma, Parma, Italy, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸Feinstein Institutes for Medical Research, Melrose, MA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Northwell Health, Manhasset, NY, ¹³Broad Institute, Cambridge, MA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Brigham and Women's Hospital, Everett, MA, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Multiple Institutions, Multiple
Background/Purpose: There is a pressing need to identify novel therapeutic targets in lupus nephritis. Multiomic approaches hold great potential for discovery. We integrated urine proteomics…
Abstract Number: 0342 • ACR Convergence 2021
RAIL Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis
Ellen Cody¹, Scott Wenderfer², Qing Ma¹, Angela Merritt¹, Prasad Devarajan¹ and Hermine Brunner¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Baylor College of Medicine, Houston, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a diagnostic and therapeutic challenge, particularly lupus nephritis (LN). We described a composite score, the Renal Activity Index for…
Abstract Number: 0973 • ACR Convergence 2021
Modeling of Clinical Phenotypes in SLE Based on Platelet Transcriptomic Analysis and FCGR2a Biallelic Variants
MacIntosh Cornwell¹, Hanane EL Bannoudi², Elliot Luttrell-Williams¹, Khrystyna Myndzar¹, Alexis Engel³, Peter Izmirly⁴, H. Michael Belmont⁵, Robert Clancy⁶, Jeffrey Berger¹, Kelly Ruggles¹ and Jill Buyon⁶, ¹New York University, New York, NY, ²NYU Langone Health, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY
Background/Purpose: The clinical heterogeneity of SLE with its complex pathogenesis remains challenging as we strive to provide optimal management. The contribution of platelets to endovascular…
Abstract Number: 1503 • ACR Convergence 2021
Putting the Pieces on the Board: Mapping SLE Nephritis Biopsies from the Accelerating Medicines Project Using High-Density Immunofluorescence Imaging
Craig Smuda¹, Anna Eichinger², Robert Clancy², Jill Buyon³ and Boris Reizis⁴, ¹NYU Grossman School of Medic ine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: The Accelerating Medicines Project (AMP) has enabled significant increases in understanding of SLE nephritis pathology, providing a profile of dozens of leukocyte subsets within…
Abstract Number: 0350 • ACR Convergence 2021
EPI-SIGN: Epigenetic SLE Indicators of Glomerular Nephritis
Ashira Blazer¹, Olusola Ayanlowo², Will Liao³, Dzifa Dey⁴, Jasmin Divers⁵, Uyiekpen Ima-Edomwonyin⁶, Hakeem Olaosebikan⁷, Cristina Lanata⁸, Girish Nadkarni⁹, Jill Buyon¹, Peter Izmirly¹⁰ and Timothy Niewold¹¹, ¹NYU School of Medicine, New York, NY, ²College of Medicine University of Lagos, New York, NY, ³New York Genome Center, New York, NY, ⁴University of Ghana, Accra, Ghana, ⁵NYU Langone Hospital - Long Island, Mineola, NY, ⁶Lagos State University Teaching Hospital, Lagos, Nigeria, ⁷Lagos University State Teaching Hospital, Lagos, Nigeria, ⁸University of California San Francisco, Moss Beach, CA, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰New York University School of Medicine, New York, NY, ¹¹Colton Center for Autoimmunity NYU School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is more common and severe in those of African Ancestry (AA) who, relative to Europeans, are twice as likely to…
Abstract Number: 1270 • ACR Convergence 2021
Disease Severity and Healthcare Costs Associated with Chronic Kidney Disease in Patients with Systemic Lupus Erythematosus
Shirley Huang¹, Amy Guisinger², Carlyne Averell¹ and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), occurring in approximately 40% of SLE patients (pts) and often resulting in…
Abstract Number: 1505 • ACR Convergence 2021
Inflammatory Dendritic Cell and Th17 Polarization in Mouse Model of Lupus Nephritis
Latha Prabha Ganesan¹, Noushin Saljoughian¹, James Turman¹, Murugesan Rajaram¹, Brad Rovin², Wael Jarjour¹ and Samir Parikh², ¹Ohio State University, Columbus, OH, ²Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: We have recently identified inflammatory dendritic cells (InfDC) in human lupus kidneys. These cells are over expressed in LN patients compared to healthy controls.…
Abstract Number: 0353 • ACR Convergence 2021
Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis
Dalena Chu¹, Noa Schwartz², Jeanette Ampudia¹, Joel Guthridge³, Judith James³, Jill Buyon⁴, Stephen Connelly¹, Maple Fung⁵, Cherie Ng¹, Chandra Mohan⁶ and Chaim Putterman⁷, ¹Equillium, Inc., La Jolla, CA, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NYU School of Medicine, New York, NY, ⁵Equillium, Inc., San Diego, CA, ⁶University of Houston, Houston, TX, ⁷Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. While LN pathogenesis has yet to be…
Abstract Number: 1271 • ACR Convergence 2021
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Shirley Huang¹, Amy Guisinger² and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Approximately 40% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN), of whom up to 20% may progress to end-stage kidney disease…
Abstract Number: 1627 • ACR Convergence 2021
Long Term Follow-Up of Patients with Childhood-Onset Lupus Nephritis After Transition to Adult Care
Dahima Cintrón¹, Suheiry Márquez¹ and Luis Vilá², ¹University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Approximately 20% of patients with systemic lupus erythematosus (SLE) are diagnosed before 18 years of age. Pediatric patients have a worse disease course when…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].